Page 1

[ Nurix logo ] Exhibit 99.1 Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL - 306 trial comparing bexobrutideg with pirtobrutinib in relapsed / refractory CLL / SLL Advanced bexobrutideg combination strategy with initiation of recruiting for the Phase 1b / 2 NX - 5948-203 study Earned $ 27M from Gilead , Pfizer and Sanofi collaborations , including a $ 10M milestone from Sanofi for first patient dosed in the STAT6 degrader Phase 1 trial Advanced NX - 1607 into Phase 1b expansion cohorts in MSS CRC , NSCLC , CRPC and melanoma with the first patient dosed in September 2026 Following receipt of the $ 700 million upfront as part of the close of the Roche collaboration , Nurix has $ 1.1 billion in cash , cash equivalents and marketable securities , and runway into the second half of 2029 BRISBANE , Calif . , October 12 , 2026 ( GLOBE NEWSWIRE ) -- Nurix Therapeutics , Inc. ( Nasdaq : NRIX ) , a clinical - stage biopharmaceutical company focused on the discovery , development and commercialization of targeted protein degradation medicines , today reported financial results for the fiscal quarter ended August 31 , 2026 , and highlighted significant corporate updates on partnered clinical programs and its wholly owned oncology portfolio . " The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto - immune disease , " said Arthur T. Sands , M.D. , Ph.D. , president and chief executive officer of Nurix . “ At the same time , Sanofi advanced our oral STAT6 degrader into the clinic , and we advanced our CBL - B inhibitor NX - 1607 into Phase 1b expansion cohorts across four solid tumor indications . " Program Highlights * Oncology Pipeline Bexobrutideg Global Collaboration with Roche During the quarter , Nurix and Roche entered into the global collaboration to co - develop and co - commercialize bexobrutideg across malignant hematology , immunology and neurology , cleared the Hart - Scott - Rodino requirement , and began executing with the initiation of the Phase 3 DAY Break CLL - 306 study . The collaboration is designed to support Nurix's comprehensive clinical development strategy spanning multiple hematologic malignancies and expansion into immune - mediated diseases , including chronic spontaneous urticaria ( CSU ) and multiple sclerosis ( MS ) . Under the agreement , development costs are shared 40 % by Nurix and 60 % by Roche ; profits and losses in the United States will be shared equally ; and Nurix is eligible to receive tiered royalties on ex - U.S . sales . Bexobrutideg Registrational Development in CLL / SLL • • • • Enrolled the first patient in DAYBreak CLL - 306 ( NCT07516093 ) , the first Phase 3 trial of bexobrutideg . The global , randomized registrational study is designed to evaluate the potential superiority of bexobrutideg versus pirtobrutinib in approximately 620 patients with relapsed / refractory CLL / SLL whose disease has progressed following prior covalent BTK inhibitor therapy . Patients in DAYBreak CLL - 306 are randomized 1 : 1 to receive bexobrutideg 600 mg orally once daily or pirtobrutinib . The dual primary endpoints are objective response rate and progression - free survival , each assessed by an independent review committee . The study is designed to support global regulatory submissions . Continued enrollment in DAYBreak CLL - 201 ( NCT07221500 ) , the pivotal single - arm Phase 2 trial designed to support a potential Accelerated Approval submission in patients with relapsed / refractory CLL whose disease has progressed following treatment with a covalent BTK inhibitor , a BCL2 inhibitor and a non - covalent BTK inhibitor . Bexobrutideg Combination Development Initiated recruiting for the Phase 1b / 2 NX - 5948-203 study ( NCT07520006 ) , which will evaluate bexobrutideg in combination with standard - of - care therapies in patients with CLL / SLL . • The initial cohort is designed to evaluate bexobrutideg in combination with venetoclax .